<p>Hepatic Arterial Infusion Oxaliplatin Plus Oral S-1 Chemotherapy in Gastric Cancer with Unresectable Liver Metastases: A Case Series and Literature Review</p>

Abstract

The use of hepatic artery infusion (HAI) as a regional therapy against liver metastasis has rarely been reported in gastric cancer. This study aimed to evaluate the efficacy and safety of HAI oxaliplatin plus oral S-1 chemotherapy in first-line palliative therapy for gastric cancer with multiple liver metastases (GCLM). Methods: We reviewed the records of five patients with GCLM who received HAI oxaliplatin (70-80 mg/m 2 2 hrs d1,15) administered via a port-catheter system and S-1 with oral (35-40 mg/m 2 twice daily for d1-14, 28 days for one cycle). Follow-up examination and efficacy evaluation were executed periodically. Results: Until the 4th cycle response evaluation, the local effective rate and control rate were 40% and 80%, respectively; only one patient developed progression. HAI chemotherapy had a better local control against liver metastases (median progression-free survival: hepatic, 8.8 months vs. extrahepatic, 6.2 months), accompanied by less systemic toxicity, decreased tumour markers and symptomatic relief. Conclusion: HAI oxaliplatin plus oral S-1 chemotherapy can be considered as a new choice of first-line treatment for GCLM, which is also a good approach for controlling extrahepatic lesions with less adverse events.

Analysis of Hepatic Artery Infusion (HAI) Chemotherapy Using Randomized Trials of Floxuridine (FUDR) for Colon Cancer Patients with Multiple Liver Metastases

“…It also features a catheter-connected exit. The fluid container applied for charging consists of fluorocarbon liquid which is warmed by using the temperature of patient's body and changed to a gas phase, which keeps the drug chamber at a constant pressure [ 16 , 17 ]. The pressure applied by the vapor in homeostasis with the steady liquid phase and independent of volume at a given temperature.…”

Successful Treatment with Hepatic Arterial Infusion Chemotherapy in a Breast Cancer Patient with Multiple Liver Metastases Who Declined Systemic Therapy

“…However, LM is a life-threatening disease to be cared for in BC [9]. HAIC has been used to treat gastrointestinal malignancies with LM expecting high tumor response followed by extended survival rate with low toxicity [10][11][12]. However, the benefit of HAIC for BC patients with LM remains unclear although some retrospective studies reported that HAIC was effective for LM refractory to conventional systemic chemotherapy [13,14].…”

Hepatic arterial infusion chemotherapy and trastuzumab in gastric cancer with liver metastases: a case report

“…Therefore, researchers have turned their attention to the application of HAIC in GCLM. Wang et al reviewed five GCLM patients who received HAI oxaliplatin and S-1 oral treatment, the objective response rate was 40%, the disease control rate was 80%, and HAI chemotherapy had better local control of liver metastasis, with a median PFS of 8.8 months (21). Ojima et al retrospectively evaluated the efficacy of HAIC for synchronous GCLM, ORR of HAIC was 83%, there were no serious side effects, and the median survival time (MST) of the HAIC group was 19.2 months (22).…”